Global Research Trends on Precision Cancer Medicine-related Rashes (2008-2021): A Bibliographic Study

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Sep 12

PMID 36091077

Authors

Fangmin Zhao

Rui Yu

Shuyi Chen

Shuya Zhao

Lin Sun

Zeting Xu

Yao Zhang

Shuying Dai

Gaochenxi Zhang

Qijin Shu

Affiliations

Soon will be listed here.

Abstract

Background: Precision cancer medicine-related rashes are a kind of skin and mucous lesions caused by precision therapy. More and more evidences indicated that such events should not be ignored in the course of anti-tumor therapy. Since cancer treatment entered the "Precision Era", there has been a rapid increase in this field. However, there was few bibliometric studies to provide an overall review of this field. This study aims to evaluate the literature output and trends in researches on precision cancer medicine-related rashes from a global perspective.

Methods: Collected publications on precision cancer medicine-related rashes from the Web of Science Core Collection database, which were limited to articles and reviews in English. Microsoft Excel, VOS viewer and CiteSpace V were used for quantitative and visual analysis.

Results: A total of 1,229 papers were identified. From 2008 to 2021, annual publications increased year by year. The United States published the most papers in this field (44.9%) and ranking first in citation frequency (19,854 times) and H-index (69). The University of Texas system ranks first with 98 papers published. Lacouture M.E and Robert C were the principal investigators. Cancers has the largest number of articles published, with 70 articles. In recent years, there have been research hotspots related to immunotherapy, including ipilimumab, immunotherapy, tumor microenvironment, association, checkpoint inhibitor, and cutaneous adverse event.

Conclusion: Precision cancer medicine-related rashes are a hot research topic in oncology. The number of relevant publications will increase dramatically. "Checkpoint inhibitors", "skin adverse events", "associations" and "tumor microenvironment" may become research hotspots in the future.

Citing Articles

Global research trends in precision-targeted therapies for systemic lupus erythematosus (2003-2023): A bibliographic study.

Yuan Z, Zhang W, Jin Z, Wang Y, Lin Z, Xie Z Heliyon. 2024; 10(13):e33350.

PMID: 39050478 PMC: 11268211. DOI: 10.1016/j.heliyon.2024.e33350.

Spotlight on macrophage pyroptosis: A bibliometric and visual analysis from 2001 to 2023.

Peng Z, Xiao H, Tan Y, Zhang X Heliyon. 2024; 10(11):e31819.

PMID: 38845992 PMC: 11154638. DOI: 10.1016/j.heliyon.2024.e31819.

Global trends and hotspots in research of robotic surgery in oncology: A bibliometric and visual analysis from 2002 to 2021.

Lu H, Han T, Li F, Yang J, Hou Z Front Oncol. 2022; 12:1055118.

PMID: 36439475 PMC: 9691977. DOI: 10.3389/fonc.2022.1055118.

References

Naik P . Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. Dermatol Ther (Heidelb). 2021; 11(5):1481-1496. PMC: 8484371. DOI: 10.1007/s13555-021-00583-z. View

Phillips G, Freites-Martinez A, Wu J, Chan D, Fabbrocini G, Hellmann M . Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics. JAMA Dermatol. 2018; 155(2):249-251. PMC: 6439535. DOI: 10.1001/jamadermatol.2018.4560. View

Lee Y, Kim H, Won C, Chang S, Lee M, Choi J . Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy. J Korean Med Sci. 2019; 34(26):e186. PMC: 6609422. DOI: 10.3346/jkms.2019.34.e186. View

Quach H, Johnson D, LeBoeuf N, Zwerner J, Dewan A . Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol. 2021; 85(4):956-966. DOI: 10.1016/j.jaad.2020.09.054. View

Ramos-Casals M, Brahmer J, Callahan M, Flores-Chavez A, Keegan N, Khamashta M . Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020; 6(1):38. PMC: 9728094. DOI: 10.1038/s41572-020-0160-6. View

Quach H, Dewan A, Davis E, Ancell K, Fan R, Ye F . Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma. JAMA Oncol. 2019; 5(6):906-908. PMC: 6567826. DOI: 10.1001/jamaoncol.2019.0046. View

Wang Y, Kong D, Wang C, Chen J, Li J, Liu Z . A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials. Technol Cancer Res Treat. 2020; 19:1533033820967454. PMC: 7588773. DOI: 10.1177/1533033820967454. View

Ugurel S, Rohmel J, Ascierto P, Becker J, Flaherty K, Grob J . Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. Eur J Cancer. 2020; 130:126-138. DOI: 10.1016/j.ejca.2020.02.021. View

Dousset L, Boniface K, Seneschal J . Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies. G Ital Dermatol Venereol. 2019; 154(4):435-443. DOI: 10.23736/S0392-0488.18.06254-5. View

10.

Gracia-Hernandez M, Munoz Z, Villagra A . Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers. Cancers (Basel). 2021; 13(24). PMC: 8699560. DOI: 10.3390/cancers13246180. View

11.

Passaro A, Di Maio M, Del Signore E, Gori B, de Marinis F . management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. Clin Lung Cancer. 2014; 15(4):307-12. DOI: 10.1016/j.cllc.2014.04.006. View

12.

Hirsch J . An index to quantify an individual's scientific research output. Proc Natl Acad Sci U S A. 2005; 102(46):16569-72. PMC: 1283832. DOI: 10.1073/pnas.0507655102. View

13.

Espinosa M, Abad C, Kurtzman Y, Abdulla F . Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers. Front Oncol. 2021; 11:605941. PMC: 8190330. DOI: 10.3389/fonc.2021.605941. View

14.

Paz-Ares L, Ramalingam S, Ciuleanu T, Lee J, Urban L, Bernabe Caro R . First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. J Thorac Oncol. 2021; 17(2):289-308. DOI: 10.1016/j.jtho.2021.09.010. View

15.

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View

16.

Akano Y, Kuribayashi K, Funaguchi N, Koda Y, Fujimoto E, Mikami K . Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases. In Vivo. 2019; 33(2):507-514. PMC: 6506318. DOI: 10.21873/invivo.11503. View

17.

Johnson D, Balko J, Compton M, Chalkias S, Gorham J, Xu Y . Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016; 375(18):1749-1755. PMC: 5247797. DOI: 10.1056/NEJMoa1609214. View

18.

Chan K, Bass A . Autoimmune complications of immunotherapy: pathophysiology and management. BMJ. 2020; 369:m736. DOI: 10.1136/bmj.m736. View

19.

Yamamoto K, Shinomiya K, Ioroi T, Hirata S, Harada K, Suno M . Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients. Target Oncol. 2015; 11(1):93-9. DOI: 10.1007/s11523-015-0382-9. View

20.

McLellan B, Ciardiello F, Lacouture M, Segaert S, Van Cutsem E . Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015; 26(10):2017-26. PMC: 4576906. DOI: 10.1093/annonc/mdv244. View